SCHEMBL30009580

SCHEMBL30009580

O=S(=O)(CCCC(F)(F)F)Nc1ccc(-c2ncnc3[nH]ccc23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 8/20 0.59
IKBKB O14920 1/20 0.53
CHUK O15111 1/20 0.53
KIT P10721 7/20 0.53
JAK2 O60674 7/20 0.51
TYK2 P29597 4/20 0.51
CIT O14578 1/20 0.47
JAK3 P52333 3/20 0.46
BTK Q06187 3/20 0.43
FLT3 P36888 2/20 0.43
AURKA O14965 1/20 0.43
DAPK3 O43293 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
NTRK1 P04629 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
IGF1R P08069 1/20 0.43
MET P08581 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009244 0.93 IKBKB (0.55) JAK1IKBKBCHUKKITJAK2
SCHEMBL30008756 0.87 IKBKB (0.56) JAK1IKBKBCHUKKITJAK2
SCHEMBL30009793 0.85 KIT (0.71) JAK1IKBKBCHUKKITJAK2
SCHEMBL30008726 0.83 JAK1 (0.47) JAK1KITJAK2TYK2JAK3
SCHEMBL30009301 0.83 JAK1 (0.59) JAK1IKBKBCHUKKITJAK2
SCHEMBL30009538 0.82 KIT (0.69) JAK1IKBKBCHUKKITJAK2
SCHEMBL30009248 0.82 IKBKB (0.61) JAK1IKBKBCHUKKITJAK2
SCHEMBL24805256 0.78 IKBKB (0.70) IKBKBCHUKKITJAK2CIT
SCHEMBL20918901 0.75 JAK1 (1.00) JAK1
SCHEMBL30009334 0.74 IKBKB (0.60) JAK1IKBKBCHUKKITJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 JAK1 83/4885IKBKB 294/4885CHUK 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.